| May 16 2025 |
McDermott+ Check-Up: May 16, 2025 |
McDermott Will & Emery |
| May 16 2025 |
Reflections on the FDLI 2025 Annual Conference – Differing Tones, Shared Goals |
Sheppard, Mullin, Richter & Hampton LLP |
| May 15 2025 |
“AI Policy Roadmap” Released by AdvaMed to Guide Regulators |
Foley & Lardner LLP |
| May 15 2025 |
Focus, Fairness and Efficiency: DOJ Reveals Administration’s Plans for Enforcement of Corporate and White-Collar Crime |
Polsinelli PC |
| May 15 2025 |
Trump Administration Announces New Executive Order to Promote Domestic Production of Biopharmaceuticals |
Polsinelli PC |
| May 15 2025 |
New EO Targets Prescription Drug Costs – and Drug Manufacturers, Hospitals, and Health Centers |
McDermott Will & Emery |
| May 15 2025 |
Drug Pricing: Trump Signs “Most Favored Nation” Executive Order |
Foley & Lardner LLP |
| May 15 2025 |
EAB Issues Consent Agreement and Final Order for TSCA Section 5 Violations |
Bergeson & Campbell, P.C. |
| May 15 2025 |
No Article III Appellate Standing Under the Sun |
McDermott Will & Emery |
| May 15 2025 |
Texas Launches Another Investigation into Healthy Claims in Cereals |
Keller and Heckman LLP |
| May 15 2025 |
FDA Approves Three New Natural Food Colors |
Keller and Heckman LLP |
| May 15 2025 |
FDA and HHS Announce Next Steps in “Operation Stork Speed” |
Keller and Heckman LLP |
| May 15 2025 |
Hatch-Waxman or Not, Clinical Trials Aren’t Subject to Injunction |
McDermott Will & Emery |
| May 15 2025 |
FDA Announces Expanded Use of Unannounced Inspections at Foreign Manufacturing Facilities |
Keller and Heckman LLP |
| May 15 2025 |
FDA and NIH Launch Joint Nutrition Regulatory Science Program |
Keller and Heckman LLP |
| May 15 2025 |
Up in Smoke: Statutory Trademark Damages Can Exceed Actual Damages |
McDermott Will & Emery |
| May 15 2025 |
FDA Extends Comment Period for Front-of-Package Nutrition Labeling Rule |
Keller and Heckman LLP |
| May 15 2025 |
U.S. State PFAS Initiatives — A Conversation with Richard E. Engler, Ph.D. and Carla N. Hutton [Podcast] |
Bergeson & Campbell, P.C. |
| May 15 2025 |
FDA Releases 2023 CORE Annual Report |
Keller and Heckman LLP |
| May 15 2025 |
FDA to Rehire Some Staff |
Keller and Heckman LLP |
| May 15 2025 |
Proposed System to Define Ultra-Processed Foods |
Keller and Heckman LLP |
| May 14 2025 |
This Week in 340B: May 6 – 12, 2025 |
McDermott Will & Emery |
| May 14 2025 |
FAQ: Employee Stock Ownership Plans (“ESOPs”) in the Cannabis Industry |
Blank Rome LLP |
| May 14 2025 |
Have You Done Your Part to Comply with Part 2 Changes? |
Katten |
| May 14 2025 |
Pennsylvania PUC Reviews Data Center Impacts Amid New Energy Plan |
Polsinelli PC |
| May 14 2025 |
NC Legislature Considers Comprehensive Hemp Regulation: What Businesses Need to Know |
Ward and Smith, P.A. |
| May 12 2025 |
Appeals Court Rejects AstraZeneca’s Challenge to Medicare Drug Price Negotiation Program |
Mintz |
| May 12 2025 |
European Commission Previews New Round of Countermeasures Against the United States |
Squire Patton Boggs (US) LLP |
| May 9 2025 |
Minnesota Employment Legislative Update 2025, Part II: It’s Déjà Vu—Lengthy Omnibus Bills, Buried Employment Law Changes |
Ogletree, Deakins, Nash, Smoak & Stewart, P.C. |
| May 9 2025 |
Onshoring Pharma Ops: Reading Recent EO and Policy Tea Leaves |
Sheppard, Mullin, Richter & Hampton LLP |
| May 9 2025 |
McDermott+ Check-Up: May 9, 2025 |
McDermott Will & Emery |
| May 8 2025 |
Is “Compromise” a Four-Letter Word? Alabama Legislature Passes Comprehensive Consumable Hemp Reform Bill |
Bradley Arant Boult Cummings LLP |
| May 8 2025 |
DEA Proposed Rule for Special Registrations for Telemedicine and Limited State Telemedicine Registrations |
Bradley Arant Boult Cummings LLP |
| May 8 2025 |
Litigation Minute: Tough to Swallow: Increased State Regulation of and Attention on Contaminants in Food |
K&L Gates LLP |
| May 8 2025 |
AI's Obstacles in Chemical Innovation: Polyani Paradox Impact |
Foley & Lardner LLP |
